Skip to main
VNDA
VNDA logo

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 21%
Hold 29%
Sell 0%
Strong Sell 7%

Bulls say

Vanda Pharmaceuticals Inc has demonstrated significant growth potential, particularly through an 18% increase in net product sales of Fanapt compared to the year-ago period, with expectations for sustained revenue growth in 2025 driven by the uptake of Fanapt in bipolar disorder and ongoing interest in Ponvory. The company's fourth-quarter 2024 results showed a robust increase in new patient starts, with new-to-brand prescriptions rising by over 160%, indicating strong market demand and potential for future profitability. Vanda's healthy balance sheet, coupled with ambitious long-term revenue goals and strategic new product launches, further supports a positive outlook for the company's financial performance.

Bears say

Vanda Pharmaceuticals Inc faces several significant risks that contribute to a negative outlook on its stock, including slower-than-expected commercial traction for its key products, Fanapt and Ponvory, along with accelerated generic erosion impacting revenue. The company is also facing negative pricing developments, particularly concerning Medicare reimbursement, and potential regulatory setbacks with late-stage pipeline candidates like tradipitant. Additionally, there are concerns regarding the possibility of adverse developments related to mergers and acquisitions, shareholder base destabilization, and medium- to long-term dilution risks, all of which could undermine financial stability and growth projections.

Vanda Pharmaceuticals (VNDA) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 21% recommend Buy, 29% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 14 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.